Acute haemothorax secondary to ibrutinib: A case report

[摘要] Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphomathat frequently follows an aggressive clinical course, with 5-year overall survival (OS) ranging from 17% to 85% [1]. Previous management comprised intensive chemotherapy regimens with or withoutautologous stem cell transplantation, however this was limited bychemotherapy-related toxicities especially in older patients. There hassince been a trend towards the use of chemotherapy-free treatments,with the aim of prolonging disease remission while minimising toxicity.Ibrutinib is an orally administered first-generation Bruton’s tyrosinekinase (BTK) inhibitor that was licenced as first-line treatment duringthe COVID-19 pandemic [2]. It binds to cysteine 481 within the ATPbinding site of the BTK kinase domain. It also reacts with other TECkinases (BMX, ITK, BLK) distributed in various tissues, resulting in sideeffects such as atrial fibrillation and bleeding [3–5]. Here, we report acase of acute haemothorax in a patient with MCL, 3 months after theinitiation of ibrutinib as first-line therapy.